

# Subsidence and Survivorship of a Cementless, Triple Tapered Collared Femoral Stem in Total Hip Arthroplasty: A Minimum Two-Year Follow-Up

Brandon K Couch MD<sup>1</sup>, Allyson N Pfeil<sup>1</sup>, Joshua Taylor<sup>1</sup>, Ecem Kilic MS<sup>2</sup>, Corey Hryc PhD<sup>1</sup>, Ugonna H Ihekweazu MD<sup>1</sup>

<sup>1</sup>Fondren Orthopedic Research Institute, Fondren Orthopedic Group, Texas Orthopedic Hospital, Houston, Texas, USA, <sup>2</sup>School of Engineering Medicine, Texas A&M University, Houston, Texas, USA

Allyson.pfeil@fondren.com

**Disclosures:** Brandon K Couch (N), Allyson N Pfeil (N), Joshua Taylor (N), Ecem Kilic (N), Corey Hryc (5-Johnson & Johnson MedTech), Ugonna H Ihekweazu (1-Fondren-LTD; 2-Johnson & Johnson MedTech; 3B-Johnson & Johnson MedTech, Zimmer Biomet; 4-VISIE, RevelAI, ROMTech; 5-Johnson & Johnson MedTech; 8-Journal of Arthroplasty; 9-AAHKS Board of Directors, Arthritis Foundation)

**INTRODUCTION:** Clinical outcomes and survivorship of triple taper femoral stems are of increasing importance given rising total hip arthroplasty (THA) utilization. This study sought to report THA outcomes using a single cementless, triple tapered femoral stem system with a minimum follow-up of two years.

**METHODS:** A retrospective chart review was conducted of patients who underwent primary THA using a cementless, collared, triple taper femoral stem (Actis; Johnson & Johnson MedTech) by four surgeons with a two-year minimum follow-up. Radiographic subsidence was assessed at 6-weeks and most recent film. Clinically relevant subsidence was defined as  $\geq 3$  mm. Implant survivorship and reoperation rates were analyzed between sex and Dorr classification subgroups with Chi-Square tests. This study was approved by the IRB committee.

**RESULTS:** 307 THAs (284 patients) were included, with an average age of  $63.8 \pm 10.4$  years and follow-up of  $37.3 \pm 12.6$  months. The cohort consisted of 178 females (60.0%). 76.2% of patients exhibited Dorr type A femurs, and 23.8% exhibited Dorr type B, with no Dorr type C. The mean 6-week subsidence was  $0.5 \pm 1.7$ mm and most recent (average 30.1 months) was  $1.1 \pm 1.7$ mm. Clinically relevant subsidence rates were 1.6% and 5.1% at 6-weeks and most recent, respectively. Femoral revision-free survivorship was 99.4%, overall revision-free survivorship 97.4%, and reoperation-free survivorship 95.1% (Figure 1). Periprosthetic fractures were noted in 0.65% of THAs. No difference was noted in subsidence or survivorship between male and female patients ( $P=.45$  and  $P=.59$ , respectively) or Dorr A and Dorr B femurs ( $P=.56$  and  $.19$ , respectively; Table 1). No difference was found in the canal fill between subsidence and no subsidence cohorts ( $0.76 \pm 0.09$  v.  $0.76 \pm 0.07$ ,  $P>.99$ ).

**DISCUSSION:** This study demonstrates minimal subsidence as well as excellent early outcomes of a single, triple taper femoral stem. As use of this stem design continues to rise, further research is needed to determine long-term survivorship of these implants.

**SIGNIFICANCE/CLINICAL RELEVANCE:** Understanding subsidence and femoral stem migration patterns, particularly in various femora, is critical to achieving and maintaining proper fixation in cementless THA.

**ACKNOWLEDGEMENTS:** We acknowledge the Fondren Orthopedic Research Institute at the Texas Orthopedic Hospital who supported the study team.


**IMAGES & TABLES:**

**Table 1.** Comparisons Between Subsided and Non-Subsided Hips.

Parameter	No Clinical Subsidence (n=240)	Clinical Subsidence (at most recent) (n=13)	P value
Approach			<b>.0478</b>
-DA	117 (48.75)	10 (76.92)	-
-Posterior	123 (51.25)	3 (23.08)	-
Alignment			<b>.0008</b>
-Neutral	190 (79.17)	5 (38.46)	-
-Varus	4 (1.67)	0 (0)	-
-Valgus	46 (19.17)	8 (61.54)	-
Dorr Classification			.5644
-A	183 (76.25)	9 (69.23)	-
-B	57 (23.75)	4 (30.77)	-
CFI	$3.70 \pm 0.66$	$3.37 \pm 0.56$	.0783
-Normal	186 (77.50)	11 (84.62)	.5473
-Stovepipe	36 (15.0)	2 (15.38)	.9698
-Champagne Flute	18 (7.5)	0 (0)	.3056
AP CBR	$0.41 \pm 0.07$	$0.42 \pm 0.08$	.6189
LAT CBR	$0.47 \pm 0.09$ (n=207)	$0.51 \pm 0.14$ (n=9)	.2048
MCF LT	$0.76 \pm 0.07$	$0.76 \pm 0.09$	>.9999
Calcar Contact	159 (66.25)	7 (53.85)	.8845
Reoperations	12 (5.0)	0 (0)	.4088
Revisions	6 (2.5)	0 (0)	.5640

Note: 54 hips without a most recent film were not included in this table.

**Abbreviations:** AP=anteroposterior, CBR=canal bone ratio, CFI=canal flare index, DA=direct anterior, LAT=lateral, MCF LT= Metaphyseal Canal Fill at Lesser Trochanter.



**Figure 1.** Kaplan-Meier Curves of Reoperation-Free, Any Component Revision-Free, and Femoral Component Revision-Free Survivorship.